Austrian debate: insurers should cover obesity drugs under strict conditions

An Austrian opinion piece argues that health insurers should cover GLP-1 weight-loss drugs (Ozempic, Wegovy, Mounjaro) for morbid obesity, framing obesity as a treatable disease. The claim is an editorial stance, not a policy change, and its market impact is indirect. It signals potential future reimbursement debates in Europe, which could affect drug demand and healthcare budgets.